INVA8002

INVA8002 is a novel, orally delivered, colon-targeted formulation of the 5-HT3 receptor antagonist alosetron. Developed by Invea Therapeutics (formerly InveniAI) using the AlphaMeld AI platform, it is intended for the treatment of moderate to severe ulcerative colitis (UC). The drug is specifically positioned as an add-on therapy for patients who exhibit only a partial response to anti-TNF biologics. By utilizing a proprietary delivery system that targets the colon, INVA8002 aims to maximize local therapeutic effects while minimizing systemic exposure, providing a potentially safer and more convenient oral alternative to injectable therapies for inflammatory bowel disease (IBD).